Delpharm and the Famar Group announce the acquisition by Delpharm of 5 manufacturing sites in France, Canada and the Netherlands.
Delpharm and the Famar Group are pleased to announce the acquisition by Delpharm of 5 manufacturing sites belonging to Famar, in France, Canada and the Netherlands. The transaction signed today covers the French sites located in Orléans (Loiret), L’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loire), as well as the Montreal site in Canada and that of Bladel in the Netherlands.
The transaction signed today covers the French sites located in Orléans (Loiret), L’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loire), as well as the Montreal site in Canada and that of Bladel in the Netherlands. The group of 5 sites represents a turnover of 250M€ and 1,300 employees.
Patrick Puy, President of Famar: « This acquisition by Delpharm, a reputable CDMO, represents a great opportunity for the 1300 Famar colleagues and will allow the sites to foresee a fruitful and sustainable future. »
Sébastien Aguettant, President of Delpharm: « With an headcount of 4700 people working on 17 manufacturing sites, Delpharm is reaching a new level and is now part of the top 5 CDMOs worldwide. »
Delpharm and the Famar Group wish to thank all the stakeholders who worked hard to make this deal happen, especially the French authorities, for their positive involvement.
